Rank |
Status |
Study |
1 |
Recruiting
|
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
Condition: |
Multiple Myeloma |
Interventions: |
Drug: velcade subcutaneous melphalan Prednisone; Drug: velcade cyclophosphamide Prednisone; Drug: velcade Prednisone |
Outcome Measures: |
Very Good Partial Response, Complete response rate , Partial response rate; Progression free survival; Time to progression; Time to Next Therapy; Overall survival; Time to response; Duration of response; Response rate |
|
2 |
Recruiting
|
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: |
Granulomatosis With Polyangiitis; Wegener Granulomatosis; Vasculitis |
Interventions: |
Drug: 5 mg Prednisone; Drug: 0 mg Prednisone |
Outcome Measures: |
Prednisone dose increase for disease relapse; Rates of disease flare sub types; Time to event flare; Health related quality of life; Safety Outcomes; Protocol performance |
|
3 |
Recruiting
|
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Condition: |
Granulomatosis With Polyangiitis |
Interventions: |
Drug: Prednisone 5 mg/day; Drug: Prednisone 0 mg/day |
Outcome Measures: |
Physician decision to increase glucocorticoids for disease relapse.; Time to disease flare.; Safety outcomes.; Protocol performance at VCRC Centers of Excellence.; Health-related quality of life survey; Health-related quality of life surveys |
|
4 |
Recruiting
|
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Condition: |
Cellulitis |
Interventions: |
Drug: Prednisone; Drug: Placebo |
Outcome Measures: |
Change in VAS for pain - day 1 to 48 hours; Change in erythema size - day 1 to 48 hours; Amount of pain medication - day 1 to 48 hours; Amount of pain medication - day 1 to 7 days; Amount of pain medication - 48 hours to 7 days; Additional Medical Assistance Post-Randomization; Disposition Trend; Adverse Events |
|
5 |
Recruiting
|
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)
Condition: |
Multiple Myeloma |
Interventions: |
Drug: Carfilzomib; Drug: Bortezomib; Drug: Melphalan; Drug: Prednisone |
Outcome Measures: |
Progression-Free Survival; Overall Survival (OS); Complete Response (CR) rate; Overall Response Rate (ORR); Change from baseline in health-related quality of life (HR-QOL) score |
|
6 |
Recruiting
|
Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Condition: |
IgA Nephropathy |
Interventions: |
Drug: Prednisone plus cyclophosphamide; Drug: Prednisone alone |
Outcome Measures: |
the changes of kidney function; the changes of proteinuria |
|
7 |
Recruiting
|
Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)
Condition: |
Cholesterol Embolism Systemic |
Interventions: |
Drug: Prednisone; Other: placebo |
Outcome Measures: |
1-year survival and 1-year renal survival (composite criteria); Number and duration of hospitalization(s); course of renal function; number of cardiovascular events; Prednisone tolerance |
|
8 |
Recruiting
|
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: |
Prostate Cancer |
Interventions: |
Drug: Docetaxel, Reolysin and Prednisone; Drug: Docetaxel and Prednisone |
Outcome Measures: |
Disease Progression; Effect of Docetaxel and Reolysin on circulating tumour cells; PSA change rate; Objective Response; Overall Survival; Determine patient tolerability and toxicity of Reolysin and Docetaxel in combination; Prognostic/Predictive molecular response |
|
9 |
Not yet recruiting
|
Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis
Conditions: |
Prednisone Dependent Asthma; Eosinophilic Bronchitis |
Interventions: |
Biological: Omalizumab (Xolair); Drug: Placebo |
Outcome Measures: |
proportion of patients with exacerbations in each study group from week 0 to week 32.; the magnitude of the reduction in the dose of Prednisone from week 12 to week 32.; change in % sputum eosinophil; Blood eosinophils; Forced Expired Volume in 1 second (FEV1); Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC); Provocative concentration causing a 20% drop in FEV1 (PC20); Asthma Control Questionnaire; Fraction of exhaled nitric oxide (FeNO) |
|
10 |
Not yet recruiting
|
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: |
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia |
Interventions: |
Biological: blinatumomab; Drug: Prednisone; Drug: vincristine sulfate; Drug: methotrexate; Drug: mercaptopurine; Drug: dasatinib; Other: laboratory biomarker analysis |
Outcome Measures: |
Overall survival (OS) (Cohort I); Incidence of dose-limiting toxicity, defined as any grade 3-4 non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) (Cohort II); Complete response (CR + CRi) rate (Cohort I); Disease-free survival; Response rates (Cohort II); OS (Cohort II); Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0; MRD negativity; Time to achieve MRD negativity |
|
11 |
Recruiting
|
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Condition: |
Prostate Cancer Metastatic |
Interventions: |
Drug: CABAZITAXEL (XRP6258); Drug: DOCETAXEL (XRP6976); Drug: Prednisone |
Outcome Measures: |
PSA response rate; Circulating tumor cells (CTCs) with response to docetaxel or cabazitaxel treatment; Progression-free survival; PSA progression-free survival rate; Objective response rate; Radiographic progression-free survival (rPFS) rate; Clinical progression-free survival (cPFS); Overall survival |
|
12 |
Recruiting
|
Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
Condition: |
Thyroid Associated Opthalmopathies |
Interventions: |
Drug: Prednisone+placebo of Doxycycline; Drug: Doxycycline+placebo of Prednisone |
Outcome Measures: |
Overall treatment response; • Health related quality of life questionnaires (GO-QoL); • Safety and tolerability as assessed by adverse events, vital signs; • Quantitative changes of rectus diameter measured by MRI scan; Relapse |
|
13 |
Recruiting
|
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Condition: |
Prostate Neoplasms |
Interventions: |
Drug: Abiraterone acetate; Drug: Prednisone; Other: Androgen deprivation therapy (ADT); Drug: Abiraterone acetate Placebo; Drug: Prednisone Placebo |
Outcome Measures: |
Overall Survival (OS); Radiographic progression-free survival (PFS); Time to next skeletal-related event; Time to prostate specific antigen (PSA) progression; Time to next subsequent therapy for prostate cancer; Time to initiation of chemotherapy; Time to Pain Progression |
|
14 |
Recruiting
|
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: |
Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Interventions: |
Drug: Alisertib; Drug: Abiraterone acetate; Drug: Prednisone |
Outcome Measures: |
Phase I: Frequency of dose limiting toxicities of Alisertib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1; Phase II: Duration of progression free survival according to the PCWG2 criteria; Change in PSA kinetics |
|
15 |
Recruiting
|
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Condition: |
Prostate Cancer |
Interventions: |
Drug: cabazitaxel, Prednisone, custirsen sodium; Drug: cabazitaxel, Prednisone |
Outcome Measures: |
Survival; Progression-free survival at Day 140 |
|
16 |
Recruiting
|
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: |
Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Interventions: |
Drug: docetaxel; Drug: pasireotide; Drug: Prednisone |
Outcome Measures: |
Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with docetaxel and Prednisone; All specific types of toxicity as assessed via NCI CTCAE version 4.0; Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with docetaxel; Percentage prostate-specific antigen (PSA) decline noted; Time to Progression (TTP); Overall Survival (OS); Pharmacokinetics (PK) parameters; Measurement of levels of IGF-1, serum chromogranin A (SCA), and neuron specific enolase (NSE), pre-therapy, post-therapy, and the change between time points and association with duration of TTP and OS; Measurements of CTC counts pre-therapy, post-therapy, and the change between time-points and association with duration of TTP and OS |
|
17 |
Unknown †
|
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
Condition: |
Focal Segmental Glomerulosclerosis |
Interventions: |
Drug: Prednisone, FK506, MMF; Drug: Prednisone |
Outcome Measure: |
proteinuria,serum protein,Scr,blood routine examination,liver function test,blood glucose and lipid test |
|
18 |
Recruiting
|
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Condition: |
Chronic GVHD |
Interventions: |
Drug: Sirolimus + calcineurin inhibitor + Prednisone; Drug: Sirolimus + Prednisone |
Outcome Measures: |
Phase II: Proportion of subjects with CR/PR; Phase III: Proportion of subjects with CR; resolution of GVHD manifestations; Phase II: Avg. daily dose % reduction of Prednisone; Phase II: Cumulative incidence of treatment failure; Phase II: Prevalence of active symptomatic chronic GVHD; Phase II: Incidence of discontinuation of all systemic immunosuppressive therapy; Phase II: Overall and cancer progression-free survival; Phase II: Serum biomarkers of chronic GVHD; Phase III: Avg. daily dose % reduction of Prednisone; Phase III: Cumulative incidence of treatment failure; Phase III: Prevalence of active symptomatic chronic GVHD; Phase III: Incidence of discontinuation of all systemic immunosuppressive therapy; Phases III: Overall and cancer progression-free survival; Phase III: Serum biomarkers of chronic GVHD |
|
19 |
Unknown †
|
Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Conditions: |
Idiopathic Retroperitoneal Fibrosis; Perianeurysmal Retroperitoneal Fibrosis; Chronic Periaortitis |
Interventions: |
Drug: Methotrexate+Prednisone; Drug: Prednisone |
Outcome Measures: |
Remission rate by the end of treatment; Reduction in size of the retroperitoneal mass on CT/MRI scans; Rate of post-treatment relapses; Treatment-related toxicity |
|
20 |
Recruiting
|
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Condition: |
Prostate Cancer |
Interventions: |
Drug: Lupron; Drug: Zoladex; Drug: Degarelix; Drug: Abiraterone Acetate; Drug: Prednisone |
Outcome Measure: |
Prostate Specific Antigen (PSA) Free Survival |
|